Optimizing the transport and storage conditions of current Good Manufacturing Practice –grade human umbilical cord mesenchymal stromal cells for transplantation (HUC-HEART Trial)
Abstract Background The HUC-HEART Trial is a clinical study of intramyocardial delivery of current Good Manufacturing Practice (cGMP)-grade human umbilical cord multipotent stromal cells (HUC-MSCs) in ischemic cardiomyopathy where 2 × 107 cells are administered to peri-infarcted myocardium. Prior t...
Gespeichert in:
Veröffentlicht in: | Cytotherapy (Oxford, England) England), 2019-01, Vol.21 (1), p.64-75 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Abstract Background The HUC-HEART Trial is a clinical study of intramyocardial delivery of current Good Manufacturing Practice (cGMP)-grade human umbilical cord multipotent stromal cells (HUC-MSCs) in ischemic cardiomyopathy where 2 × 107 cells are administered to peri-infarcted myocardium. Prior to the onset of the trial, we aimed to optimize the transport/storage conditions for obtaining the highest cell viability and proliferation rate of cells to be transplanted. Methods Cells were tested after being transported in phosphate-buffered saline (PBS) or Ringer's lactate-based (RL) transport media supplemented with human serum albumin (HSA) and/or hydroxyethyl starch (HES) at two temperatures (2–10°C or 22–24°C). Results The effects of transport conditions on cell viability following 6 h were found highest (93.4 ± 1.5) in RL-based media at 2–10°C. Karyotypes were found normal upon transportation in any of the formulations and temperatures. However, the highest proliferation rate was noted (3.1-fold increase) in RL (1% HSA) media at 2–10°C over 6 days in culture. From that point, RL (1% HSA) media at 2–10°C was used for further experiments. The maximum cell storage time was detected around 24 h at 2–10°C. Extended storage periods resulted in a decrease in cell viability but not in MSC marker expression. An increase in actin quantity was detected in hypoxia (5% O2 ) groups in early culture days; no difference was noted between hypoxic versus normoxic (21% O2 ) conditions in later days. Discussion The overall results suggest that non-commercial, simple media formulations with extended storage intervals at 2–10°C temperatures are capable of retaining the characteristics of clinical-grade HUC-MSCs. The above findings led us to use RL (1% HSA) media at 2–10°C for transport and storage in the HUC-HEART Trial; 23 patients received HUC-MSCs by August 2018; no adverse effects were noted related to cell processing and transplantation. |
---|---|
ISSN: | 1465-3249 1477-2566 |
DOI: | 10.1016/j.jcyt.2018.10.010 |